

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

Chk1 (G-4)

RRID:AB_627257

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-8408, RRID:AB_627257

Antibody Information

URL: http://antibodyregistry.org/AB_627257

Proper Citation: Santa Cruz Biotechnology Cat# sc-8408, RRID:AB_627257

Target Antigen: Chk1 (G-4)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: Immunofluorescence; Flow Cytometry; Western Blot; ELISA; Immunoprecipitation; WB, IP, IF, FCM, ELISA

Antibody Name: Chk1 (G-4)

Description: This monoclonal targets Chk1 (G-4)

Target Organism: rat, mouse, human

Antibody ID: AB_627257

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-8408

Record Creation Time: 20250819T230938+0000

Record Last Update: 20250820T042837+0000

Ratings and Alerts

No rating or validation information has been found for Chk1 (G-4).

No alerts have been found for Chk1 (G-4).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 71 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Guha Majumdar A, et al. (2026) A CHK1-mediated phosphorylation switch suppresses human Topoisomerase 1-associated genomic instability. The EMBO journal, 45(12), 4220.

Planchard D, et al. (2026) Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer cell, 44(6), 1147.

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF β complex for genomic stability. Cell reports, 44(11), 116495.

Song L, et al. (2025) Dynamic control of RNA-DNA hybrid formation orchestrates DNA2 activation at stalled forks by RNAPII and DDX39A. Molecular cell, 85(3), 506.

Cheng C, et al. (2025) Dual roles of TRPV2 in the innate immune response to cytosolic DNA: Arresting dormant and boosting activated STING. Cell reports, 45(1), 116745.

Duzanic FD, et al. (2025) H2BK120ub and its reader RNF169 sequentially regulate replication fork remodeling and stability. The EMBO journal, 44(22), 6598.

Ubieto-Capella P, et al. (2024) A rewiring of DNA replication mediated by MRE11 exonuclease underlies primed-to-naïve cell de-differentiation. Cell reports, 43(4), 114024.

Göder A, et al. (2024) DBF4, not DRF1, is the crucial regulator of CDC7 kinase at replication forks. The Journal of cell biology, 223(8).

Onji H, et al. (2024) Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. Oncogene, 43(32), 2475.

Arends T, et al. (2024) DUX4-induced HSATII transcription causes KDM2A/B-PRC1 nuclear foci and impairs DNA damage response. The Journal of cell biology, 223(5).

van de Kooij B, et al. (2024) EXO1 protects BRCA1-deficient cells against toxic DNA lesions. Molecular cell, 84(4), 659.

Muñoz S, et al. (2024) SIN3A histone deacetylase action counteracts MUS81 to promote stalled fork stability. Cell reports, 43(2), 113778.

Day CA, et al. (2024) The histone H3.3 K27M mutation suppresses Ser31phosphorylation and mitotic fidelity, which can directly drive gliomagenesis. *Current biology : CB*.

Randolph ME, et al. (2024) RNA helicase DDX3 regulates RAD51 localization and DNA damage repair in Ewing sarcoma. *iScience*, 27(2), 108925.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. *iScience*, 27(7), 109978.

Egger T, et al. (2024) Spatial organization and functions of Chk1 activation by TopBP1 biomolecular condensates. *Cell reports*, 43(4), 114064.

Lim Y, et al. (2023) In silico protein interaction screening uncovers DONSON's role in replication initiation. *Science (New York, N.Y.)*, 381(6664), eadi3448.

Li S, et al. (2023) Cytosolic DNA sensing by cGAS/STING promotes TRPV2-mediated Ca²⁺ release to protect stressed replication forks. *Molecular cell*, 83(4), 556.

Zhao Y, et al. (2023) Genome-scale mapping of DNA damage suppressors through phenotypic CRISPR-Cas9 screens. *Molecular cell*, 83(15), 2792.

Zhang J, et al. (2023) Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway. *Cell*, 186(11), 2361.